Dimitris Papamargaritis
Overview
Explore the profile of Dimitris Papamargaritis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dera A, Hinton E, Batterham R, Davies M, King J, Miyashita M, et al.
Hum Brain Mapp
. 2025 Mar;
46(4):e70192.
PMID: 40071542
Self-reported physical activity is associated with lower brain food cue responsiveness in reward-related regions, but relationships utilizing objective physical activity measurement tools have not been explored. This cross-sectional study examined...
2.
Old V, Davies M, Papamargaritis D, Choudhary P, Watson E
J Cachexia Sarcopenia Muscle
. 2025 Jan;
16(1):e13677.
PMID: 39815782
Background: Obesity is a chronic disease associated with increased risk of multiple metabolic and mental health-related comorbidities. Recent advances in obesity pharmacotherapy, particularly with glucagon-like peptide-1 (GLP-1) receptor agonists (RAs),...
3.
Goldney J, Barker M, Sargeant J, Daynes E, Papamargaritis D, Shabnam S, et al.
Diabetes Res Clin Pract
. 2025 Jan;
220:112002.
PMID: 39800277
Aims: Do associations between age at diagnosis of type 2 diabetes and vascular risk factors vary by ethnicity and deprivation? Methods: Utilising the Clinical Practice Research Datalink, we matched 16-50-year-old...
4.
Hamza M, Papamargaritis D, Davies M
Expert Opin Pharmacother
. 2024 Dec;
26(1):31-49.
PMID: 39632534
Introduction: Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is approved at the same doses (5, 10 and 15 mg)...
5.
Papamargaritis D, Al-Najim W, Lim J, Crane J, Bodicoat D, Barber S, et al.
Lancet Reg Health Eur
. 2024 May;
39:100853.
PMID: 38803628
Background: An effective prescribing pathway for liraglutide 3 mg, an approved obesity pharmacotherapy, may improve treatment access. This trial compared a targeted prescribing pathway for liraglutide 3 mg with multiple...
6.
Gogineni P, Melson E, Papamargaritis D, Davies M
Expert Opin Pharmacother
. 2024 May;
25(7):801-818.
PMID: 38753454
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance....
7.
Melson E, Ashraf U, Papamargaritis D, Davies M
Int J Obes (Lond)
. 2024 Feb;
PMID: 38302593
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite...
8.
Melson E, Miras A, Papamargaritis D
Clin Med (Lond)
. 2023 Jul;
23(4):337-346.
PMID: 37524416
Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is...
9.
Sinha R, Papamargaritis D, Sargeant J, Davies M
J Obes Metab Syndr
. 2023 Feb;
32(1):25-45.
PMID: 36750526
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and...
10.
Papamargaritis D, le Roux C, Holst J, Davies M
Cardiovasc Res
. 2022 Nov;
119(18):2825-2842.
PMID: 36448672
Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased...